US FDA approves Pegintron for treatment-failed hepatitis C patients
This article was originally published in Scrip
Schering-Plough's Pegintron (peginterferon alfa-2b) has become the first pegylated interferon to be approved by the US FDA in combination with ribavirin, for patients with hepatitis C who have previously had an unsuccessful response to interferon therapy, or who have experienced a relapse.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.